Necrobiosis lipoidica is a chronic granulomatous skin condition that predominantly affects individuals with diabetes mellitus, particularly those with type 1 diabetes. It is estimated to occur in approximately 0.3% to 1.2% of diabetic patients, though it can also appear in people without diabetes. The condition manifests as well-defined, waxy, yellowish-brown plaques with a depressed center and a violaceous border, most commonly located on the anterior shins. These lesions often exhibit telangiectasias and can become ulcerated, leading to significant pain, risk of infection, and impaired quality of life. The pathophysiology of necrobiosis lipoidica is complex and not fully understood, but a central theme in its development and persistence is the dysregulation of collagen metabolism within the dermis. Understanding how collagen—the primary structural protein of the skin—functions in the healing of necrobiosis lipoidica lesions is critical for developing effective therapeutic strategies that target tissue repair and regeneration.

The Essential Role of Collagen in Skin Structure and Wound Healing

Collagen is the most abundant protein in the human body and constitutes about 70–80% of the dry weight of the skin. It provides tensile strength, structural integrity, and elasticity to the dermal matrix. There are at least 28 known types of collagen, but in the skin, collagen types I and III predominate, forming a dense network of fibrils that support the epidermis and anchor blood vessels, nerves, and other cells.

In normal wound healing, collagen is synthesized primarily by dermal fibroblasts. The process occurs in overlapping phases: hemostasis, inflammation, proliferation, and remodeling. During the proliferative phase, fibroblasts migrate into the wound and produce collagen type III, which is later replaced by the stronger collagen type I during the remodeling phase. This deposition of collagen gradually restores the skin's mechanical properties and closes the wound. Factors such as growth factors (e.g., transforming growth factor-beta, platelet-derived growth factor), mechanical forces, and adequate vascular perfusion tightly regulate collagen synthesis. Disruption of this delicate balance leads to either excessive scarring (hypertrophic scars, keloids) or deficient healing (chronic wounds, tissue breakdown).

In necrobiosis lipoidica, the typical wound healing cascade is severely derailed. Histological examination reveals a palisading granulomatous inflammation with collagen degeneration, often described as “necrobiosis” (a term for degenerating collagen bundles). The presence of thickened, hyalinized collagen fibers interspersed with areas of complete collagen loss is a hallmark of the disease. This misbalance between collagen production and degradation is a key factor in the formation and maintenance of necrobiosis lipoidica lesions.

Collagen Dysregulation in Necrobiosis Lipoidica

Altered Collagen Synthesis and Glycation

In patients with diabetes, chronic hyperglycemia drives the non-enzymatic glycation of collagen. Advanced glycation end products (AGEs) accumulate in the dermis, cross-linking collagen fibers and rendering them resistant to normal turnover. This cross-linked collagen is both brittle and non-functional, altering the mechanical properties of the skin and impairing the ability of fibroblasts to remodel the extracellular matrix. Glycated collagen also resists breakdown by matrix metalloproteinases (MMPs), leading to an accumulation of poorly functional collagen in the tissue. This explains why necrobiosis lipoidica lesions persist for years and often fail to heal spontaneously.

Conversely, in the same lesions, there are also areas of collagen degeneration where the normal fibrillar structure is lost. This paradox—regions of both excessive cross-linking and degradation—results from a dysfunctional interplay between fibroblasts, inflammatory mediators, and abnormal vasculature. Fibroblasts in necrobiosis lipoidica exhibit reduced proliferative capacity and altered collagen synthesis profiles. Some studies have shown decreased expression of collagen types I and III in lesional skin, while others report an increase in immature collagen. This inconsistency reflects the complex microenvironment of the disease.

Inflammation and Collagen Degradation

Chronic inflammation in necrobiosis lipoidica is driven by a mixed infiltrate of lymphocytes, macrophages, and occasionally giant cells. These inflammatory cells secrete cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-1, and interferon-gamma, which can upregulate MMPs. Elevated MMP activity, particularly MMP-1, MMP-2, and MMP-9, degrades collagen fibrils, contributing to the loss of dermal structure. At the same time, TNF-α and other cytokines inhibit collagen synthesis by fibroblasts, further tipping the balance toward net collagen loss. The result is a self-perpetuating cycle of inflammation, collagen degradation, and ineffective repair.

Microvascular Injury and Impaired Nutrient Delivery

Necrobiosis lipoidica is associated with diabetic microangiopathy. Small vessel disease leads to hypoperfusion of the dermis, reducing the delivery of oxygen, glucose, amino acids, and other nutrients essential for collagen synthesis. Fibroblasts require adequate oxygenation to produce hydroxylated collagen molecules; hypoxia can cause under-hydroxylation and secretion of unstable collagen that is rapidly degraded. The lack of proper vascular support also impairs the clearance of waste products and inflammatory mediators, allowing the inflammatory environment to persist. This ischemic milieu further cripples collagen repair processes.

Factors That Influence Collagen's Healing Capability in Necrobiosis Lipoidica

Glycemic Control

Poor glycemic control is a well-established risk factor for the development and progression of necrobiosis lipoidica. Elevated blood glucose levels directly increase the formation of AGEs and promote cross-linking of collagen. Maintaining near-normal hemoglobin A1c levels may reduce AGE accumulation and improve collagen turnover. However, even in patients with excellent diabetic control, lesions can persist, indicating that other factors are at play.

Inflammatory Status

Systemic inflammation, common in diabetes, can be measured by markers such as C-reactive protein. In necrobiosis lipoidica, local inflammation is the dominant driver of collagen dysregulation. Therapies that reduce inflammation, such as topical corticosteroids or systemic agents like hydroxychloroquine, may dampen the inflammatory cascade and indirectly support collagen remodeling by reducing MMP activity and allowing fibroblasts to function more normally.

Vascular Health

Peripheral arterial disease exacerbates tissue hypoxia. Improving blood flow through exercise, smoking cessation, and management of hypertension and hyperlipidemia can enhance oxygen delivery to the lower extremities. In advanced cases, revascularization procedures may be considered. Even modest improvements in perfusion can positively affect fibroblast activity and collagen synthesis.

Nutritional Factors

Collagen synthesis requires specific nutrients: vitamin C (a cofactor for proline and lysine hydroxylation), copper (for lysyl oxidase-mediated cross-linking), zinc, and adequate protein intake. Many patients with chronic conditions have suboptimal nutrition. Supplementation with vitamin C, vitamin E, and other antioxidants may help counteract oxidative stress that damages collagen and inhibits fibroblast function. However, rigorous evidence in necrobiosis lipoidica is lacking.

Age and Duration of Disease

Both aging and prolonged disease duration are associated with decreased collagen production and increased collagen degradation. Fibroblast senescence leads to reduced synthetic capacity. Older patients may require more aggressive and prolonged treatment to stimulate collagen repair. The density and quality of collagen also decline with age, making the skin more vulnerable.

Emerging and Existing Treatments That Target Collagen in Necrobiosis Lipoidica

Topical Agents to Stimulate Collagen Production

Several topical treatments have been explored for their ability to upregulate collagen synthesis in necrobiosis lipoidica lesions. Topical corticosteroids are commonly used to reduce inflammation, but they can also suppress fibroblast activity and collagen production, leading to skin atrophy with prolonged use. This trade-off must be carefully managed. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) offer anti-inflammatory effects without the same degree of collagen suppression. Anecdotal reports and small case series suggest some benefit.

Retinoids (e.g., tretinoin) stimulate fibroblast proliferation and collagen synthesis. However, they can also cause irritation and may not be well tolerated on the lower legs. Vitamin C (L-ascorbic acid) when applied topically, can enhance collagen production by providing a cofactor for hydroxylation. It also has antioxidant properties that protect collagen from oxidative damage. Growth factors such as recombinant human platelet-derived growth factor (becaplermin) have been used off-label in chronic wounds, but their efficacy in non-ulcerated necrobiosis lesions is uncertain.

Laser and Light-Based Therapies

Laser therapy is one of the most promising treatment modalities for stimulating collagen synthesis in necrobiosis lipoidica. Fractional CO₂ laser creates microthermal zones of injury that trigger a robust wound healing response, including neocollagenesis and remodeling of the dermal matrix. Studies have shown improved texture, reduction in plaque thickness, and even ulcer healing after several sessions. Pulsed dye laser (PDL) targets telangiectasias and reduces erythema, potentially improving blood flow and oxygenation. The laser energy may also stimulate fibroblast activity indirectly.

Low-level light therapy (LLLT) using red or near-infrared wavelengths is thought to enhance mitochondrial function in fibroblasts, boosting ATP production and collagen synthesis. Although more research is needed, early results in wound healing are encouraging.

Injectable Therapies

Intralesional corticosteroids are a mainstay for reducing inflammation in isolated plaques. However, they carry a risk of further collagen degradation and skin atrophy if overused. Intralesional platelet-rich plasma (PRP) has gained attention as a regenerative approach. PRP contains a high concentration of growth factors that can recruit fibroblasts and stimulate collagen production. Several small studies and case reports have documented improvement in necrobiosis lipoidica lesions with PRP injections, though larger controlled trials are needed.

Collagen injections (biostimulatory fillers such as poly-L-lactic acid or calcium hydroxylapatite) are used in cosmetic dermatology to stimulate neocollagenesis. Off-label use in necrobiosis has been reported, but the evidence is limited. There is also the theoretical risk of exacerbating the granulomatous inflammation, as the material itself could be engulfed by macrophages.

Systemic Medications

Systemic agents that target inflammation or collagen metabolism are reserved for refractory cases. Hydroxychloroquine is commonly used due to its immunomodulatory effects and has been shown to reduce granulomatous inflammation. It may indirectly improve collagen remodeling by decreasing the production of MMPs. Pentoxifylline improves microcirculation and has anti-inflammatory properties; it can enhance tissue oxygenation and possibly fibroblast function. Fumaric acid esters have been reported to be effective in some European studies, potentially through their effect on Th1-mediated inflammation and collagen synthesis.

Novel biologics targeting inflammatory cytokines—such as TNF-α inhibitors (infliximab, adalimumab) and IL-17/IL-23 inhibitors—are being explored for granulomatous skin diseases. Case reports suggest occasional benefit in necrobiosis lipoidica, but they are expensive and carry risks. Their effect on collagen is primarily through reducing the inflammatory milieu rather than direct stimulation.

Future Directions and Research Frontiers

Gene and Molecular Therapy

Research into the genetic basis of necrobiosis lipoidica—specifically polymorphisms in collagen-related genes—could open pathways for personalized treatments. Gene therapies aimed at increasing collagen synthesis or inhibiting MMP activity are theoretical but may become feasible. Local delivery of small interfering RNA (siRNA) to knock down MMP-1 or MMP-9 could reduce collagen degradation. Conversely, delivering plasmids encoding procollagen could boost production.

Collagen Crosslinking Inhibitors

Given the role of AGEs in damaging collagen, agents that break existing cross-links or prevent glycation are being investigated. Aminoguanidine and benfotiamine (a vitamin B1 derivative) are known to inhibit AGE formation but have not been tested specifically for necrobiosis lipoidica. Alagebrium (ALT-711) was designed to break AGE cross-links; early trials in cardiovascular disease were promising but did not reach the market. Repurposing such drugs for dermatological conditions could be a novel strategy.

Stem Cell and Extracellular Vesicle Therapies

Mesenchymal stem cells (MSCs) from adipose tissue or bone marrow secrete a wide array of growth factors and cytokines that promote tissue regeneration. Preclinical studies show that MSCs can enhance collagen deposition and improve wound healing. Extracellular vesicles (exosomes) derived from MSCs carry similar signals without the risks of living cells. Local injection of MSCs or their exosomes into necrobiosis lipoidica plaques could theoretically kickstart collagen repair, but clinical data are lacking.

Improving Vascular Support

Angiogenic therapies using vascular endothelial growth factor (VEGF) or hyperbaric oxygen therapy (HBOT) could improve the ischemic environment and thereby aid collagen synthesis. HBOT has been used in chronic wounds and may have a role in ulcerated necrobiosis. Combining such approaches with collagen-stimulating treatments might yield synergistic benefits.

Practical Clinical Recommendations for Managing Collagen in Necrobiosis Lipoidica

Based on the current understanding of collagen's role, a multimodal approach is needed:

  • Optimize glycemic control to reduce AGE formation. Aim for HbA1c below 7% if safe.
  • Address inflammation with topical or systemic anti-inflammatory agents as appropriate. Avoid prolonged use of potent corticosteroids on thin skin.
  • Improve local circulation through lifestyle modifications and, if necessary, medical management of peripheral artery disease.
  • Consider laser therapy (fractional CO₂ or PDL) for resistant plaques, especially those without ulceration.
  • Nutritional support: ensure adequate intake of vitamin C, zinc, and copper. A balanced diet with sufficient protein is essential for collagen substrate availability.
  • PRP injections can be considered for non-healing lesions, ideally in a research setting or with shared decision-making based on limited evidence.
  • Wound care: if ulceration develops, use moist wound healing principles, offloading, and infection control.

Patients should be educated about the chronic nature of necrobiosis lipoidica and the goal of slowing progression, reducing symptoms, and promoting healing when possible. Realistic expectations are important, as complete resolution is uncommon.

Conclusion

Collagen is central to the pathogenesis and healing of necrobiosis lipoidica lesions. The interplay of hyperglycemia-induced glycation, chronic inflammation, microvascular disease, and altered fibroblast function creates a deep imbalance in collagen metabolism. While no single therapy has proven universally effective, a growing understanding of collagen dynamics is guiding the development of targeted treatments. From topical agents and lasers to PRP and future biologics, the goal is to restore the skin's ability to produce and maintain a healthy collagen network. Further research—particularly well-designed clinical trials—is urgently needed to translate these insights into improved outcomes for patients suffering from this challenging condition.

External resources for further reading: